T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lam Research
LRCX
|
+$1.66B |
| 2 |
KLA
KLAC
|
+$1.39B |
| 3 |
T-Mobile US
TMUS
|
+$1.38B |
| 4 |
Eli Lilly
LLY
|
+$1.37B |
| 5 |
CSX Corp
CSX
|
+$1.18B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$4.2B |
| 2 |
Microsoft
MSFT
|
+$3.24B |
| 3 |
Amazon
AMZN
|
+$2.75B |
| 4 |
Netflix
NFLX
|
+$2.53B |
| 5 |
Apple
AAPL
|
+$2.48B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 35.66% |
| 2 | Financials | 11.78% |
| 3 | Healthcare | 11.44% |
| 4 | Consumer Discretionary | 10.75% |
| 5 | Communication Services | 10.73% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TTAM
2726
Titan America SA
TTAM
$2.9B
| $243K | ﹤0.01% |
14,733
+1,786
| +14% | +$27.9K |
|
2727
Southern First Bancshares
SFST
$612M
| $242K | ﹤0.01% |
+4,693
| New | +$225K |
|
2728
Immersion
IMMR
$248M
| $241K | ﹤0.01% |
35,410
| – | – |
|
2729
KRONOS Worldwide
KRO
$996M
| $241K | ﹤0.01% |
54,466
+30,100
| +124% | +$146K |
|
2730
Frontier Group Holdings
ULCC
$1.57B
| $240K | ﹤0.01% |
50,756
-8,595
| -14% | -$38.1K |
|
2731
Park-Ohio Holdings
PKOH
$718M
| $239K | ﹤0.01% |
11,394
| – | – |
|
2732
RE/MAX Holdings
RMAX
$265M
| $239K | ﹤0.01% |
31,475
| – | – |
|
2733
SELLAS Life Sciences
SLS
$2.5B
| $238K | ﹤0.01% |
63,026
+15,067
| +31% | +$29.3K |
|
2734
Tiptree Inc
TIPT
$677M
| $238K | ﹤0.01% |
13,020
+296
| +2% | +$5.39K |
|
|
JBS
2735
JBS N.V.
JBS
$43.8B
| $237K | ﹤0.01% |
16,429
| – | – |
|
|
FPI
2736
Farmland Partners
FPI
$425M
| $236K | ﹤0.01% |
24,328
+2,554
| +12% | +$25.6K |
|
2737
Hyliion Holdings
HYLN
$734M
| $236K | ﹤0.01% |
127,746
| – | – |
|
2738
Home Bancorp
HBCP
$569M
| $235K | ﹤0.01% |
+4,049
| New | +$225K |
|
2739
IBEX
IBEX
$482M
| $234K | ﹤0.01% |
6,106
-165
| -3% | -$6.1K |
|
2740
Toyota
TM
$223B
| $233K | ﹤0.01% |
+1,083
| New | +$220K |
|
2741
Westrock Coffee
WEST
$820M
| $233K | ﹤0.01% |
57,161
+39,100
| +216% | +$171K |
|
2742
The Joint Corp
JYNT
$119M
| $232K | ﹤0.01% |
26,504
+5,800
| +28% | +$49.2K |
|
2743
Nature's Sunshine
NATR
$269M
| $232K | ﹤0.01% |
+10,740
| New | +$197K |
|
2744
Climb Global Solutions
CLMB
$532M
| $231K | ﹤0.01% |
8,984
+884
| +11% | +$25.7K |
|
2745
Greif Class B
GEF.B
$4.22B
| $231K | ﹤0.01% |
+3,085
| New | +$205K |
|
2746
Rayonier Advanced Materials
RYAM
$570M
| $231K | ﹤0.01% |
39,121
+4,714
| +14% | +$30.6K |
|
2747
Bank of Marin Bancorp
BMRC
$462M
| $230K | ﹤0.01% |
+8,839
| New | +$227K |
|
2748
iShares Core Dividend Growth ETF
DGRO
$43.9B
| $230K | ﹤0.01% |
3,304
-1,390
| -30% | -$95.6K |
|
2749
Neuropace
NPCE
$498M
| $230K | ﹤0.01% |
14,836
+2,778
| +23% | +$37.1K |
|
2750
Unity Bancorp
UNTY
$620M
| $230K | ﹤0.01% |
+4,447
| New | +$221K |
|
Similar funds
T. Rowe Price Associates's Q4 2025 Portfolio in Review
As of Q4 2025, T. Rowe Price Associates held 3,154 positions worth $927B, down 0.78% from $935B the previous quarter. Its ten largest holdings account for 37% of the portfolio.
T. Rowe Price Associates's Q4 2025 filing shows 113 new, 1,841 increased, 860 reduced and 65 closed positions. Its largest new stake was Medline Inc: 7,325,104 shares worth $308M. The largest sale was NVIDIA, an estimated $4.2B.
By sector, the portfolio is most concentrated in Technology at 36% of assets, down from 36% a quarter earlier, followed by Financials and Healthcare.
- T. Rowe Price Associates's largest Q4 2025 buy was Medline Inc: 7,325,104 shares worth $308M.
- T. Rowe Price Associates added most to Lam Research in Q4 2025, an estimated $1.66B increase.
- T. Rowe Price Associates's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $4.2B.
- T. Rowe Price Associates fully exited Akero Therapeutics in Q4 2025, selling an estimated $181M.
- T. Rowe Price Associates's ten largest holdings make up 37% of its $927B portfolio in Q4 2025.
- T. Rowe Price Associates opened 113 new positions and closed 65 in Q4 2025.
- T. Rowe Price Associates's portfolio value fell 0.78% quarter-over-quarter to $927B.
Based on T. Rowe Price Associates's 13F filing for Q4 2025, filed 17 Feb 2026.